A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- MapKure, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT06194877
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia, United States
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- MapKure, LLC
- Target Recruit Count
- 114
- Registration Number
- NCT04249843
- Locations
- 🇦🇺
One Clinical Research, Nedlands, Perth, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇺🇸Cedars Sinai Medical Center, Beverly Hills, California, United States
© Copyright 2024. All Rights Reserved by MedPath